{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T21:48:19Z","timestamp":1793137699152,"version":"4.5.0"},"reference-count":31,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>It is uncertain to what extent watchful waiting (WW) in men with nonmetastatic prostate cancer (PCa) and a life expectancy of less than 10 years is associated with adverse consequences.<\/jats:p><\/jats:sec>Objective<\/jats:title>To report transitions to androgen deprivation therapy (ADT), castration-resistant prostate cancer (CRPC), death from PCa, or death from other causes in men treated with a WW strategy.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This nationwide, population-based cohort study included men with nonmetastatic PCa diagnosed since 2007 and registered in the National Prostate Cancer Register of Sweden with WW as the primary treatment strategy and with life expectancy less than 10 years. Life expectancy was calculated based on age, the Charlson Comorbidity Index (CCI), and a drug comorbidity index. Observed state transition models complemented observed data to extend follow-up to more than 20 years. Analyses were performed between 2022 and 2023.<\/jats:p><\/jats:sec>Exposure<\/jats:title>Nonmetastatic PCa.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Transitions to ADT, CRPC, death from PCa, and death from other causes were measured using state transition modeling.<\/jats:p><\/jats:sec>Results<\/jats:title>The sample included 5234 men (median [IQR] age at diagnosis, 81 [79-84] years). After 5 years, 954 men with low-risk PCa (66.2%) and 740 with high-risk PCa (36.1%) were still alive and not receiving ADT. At 10 years, the corresponding proportions were 25.5% (n\u2009=\u2009367) and 10.4% (n\u2009=\u2009213), respectively. After 10 years, 59 men with low-risk PCa (4.1%) and 221 with high-risk PCa (10.8%) had transitioned to CRPC. Ten years after diagnosis, 1330 deaths in the low-risk group (92.3%) and 1724 in the high-risk group (84.1%) were from causes other than PCa.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>These findings suggest that the WW management strategy is appropriate for minimizing adverse consequences of PCa in men with a baseline life expectancy of less than 10 years.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.14599","type":"journal-article","created":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T17:30:38Z","timestamp":1717522238000},"page":"e2414599","source":"Crossref","is-referenced-by-count":12,"title":["Natural History of Nonmetastatic Prostate Cancer Managed With Watchful Waiting"],"prefix":"10.1001","volume":"7","author":[{"given":"Eugenio","family":"Ventimiglia","sequence":"first","affiliation":[{"name":"Division of Experimental Oncology\/Unit of Urology, IRCCS Ospedale San Raffaele, Milan, Italy"},{"name":"Department of Surgical Sciences, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf","family":"Gedeborg","sequence":"additional","affiliation":[{"name":"Department of Surgical Sciences, Uppsala University, Uppsala, Sweden"},{"name":"Medical Products Agency, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Styrke","sequence":"additional","affiliation":[{"name":"Department of Surgical and Perioperative Sciences, Urology and Andrology, Ume\u00e5 University, Ume\u00e5, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Robinson","sequence":"additional","affiliation":[{"name":"Department of Urology, Ume\u00e5 University, Region of J\u00f6nk\u00f6ping, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e4r","family":"Stattin","sequence":"additional","affiliation":[{"name":"Department of Surgical Sciences, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Garmo","sequence":"additional","affiliation":[{"name":"Department of Surgical Sciences, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,6,4]]},"reference":[{"issue":"24","key":"zoi240497r1","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1056\/NEJMoa1807801","article-title":"Radical prostatectomy or watchful waiting in prostate cancer\u201429-year follow-up.","volume":"379","author":"Bill-Axelson","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"zoi240497r3","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/j.eururo.2007.04.002","article-title":"The 20-yr outcome in patients with well- or moderately differentiated clinically localized prostate cancer diagnosed in the pre-PSA era: the prognostic value of tumour ploidy and comorbidity.","volume":"52","author":"Adolfsson","year":"2007","journal-title":"Eur Urol"},{"issue":"22","key":"zoi240497r4","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.1001\/jama.291.22.2713","article-title":"Natural history of early, localized prostate cancer.","volume":"291","author":"Johansson","year":"2004","journal-title":"JAMA"},{"issue":"1","key":"zoi240497r5","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s12911-019-0823-y","article-title":"How to measure temporal changes in care pathways for chronic diseases using health care registry data.","volume":"19","author":"Ventimiglia","year":"2019","journal-title":"BMC Med Inform Decis Mak"},{"issue":"1","key":"zoi240497r6","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12911-022-01766-0","article-title":"Population-based estimates of age and comorbidity specific life expectancy: a first application in Swedish males.","volume":"22","author":"Van Hemelrijck","year":"2022","journal-title":"BMC Med Inform Decis Mak"},{"issue":"1","key":"zoi240497r7","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.ejca.2014.10.025","article-title":"Evaluation of data quality in the National Prostate Cancer Register of Sweden.","volume":"51","author":"Tomic","year":"2015","journal-title":"Eur J Cancer"},{"issue":"1","key":"zoi240497r8","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1093\/ije\/dyv305","article-title":"Cohort profile update: the national prostate cancer register of Sweden and prostate cancer data base\u2014a refined prostate cancer trajectory.","volume":"45","author":"Van Hemelrijck","year":"2016","journal-title":"Int J Epidemiol"},{"issue":"1","key":"zoi240497r9","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s12911-015-0217-8","article-title":"How to model temporal changes in comorbidity for cancer patients using prospective cohort data.","volume":"15","author":"Lindhagen","year":"2015","journal-title":"BMC Med Inform Decis Mak"},{"issue":"4","key":"zoi240497r10","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1097\/EDE.0000000000001358","article-title":"An aggregated comorbidity measure based on history of filled drug prescriptions: development and evaluation in two separate cohorts.","volume":"32","author":"Gedeborg","year":"2021","journal-title":"Epidemiology"},{"issue":"10","key":"zoi240497r11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0241439","article-title":"Prescription-based prediction of baseline mortality risk among older men.","volume":"15","author":"Gedeborg","year":"2020","journal-title":"PLoS One"},{"issue":"2","key":"zoi240497r12","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/bju.2015.116.issue-2","article-title":"Upper limit of cancer extent on biopsy defining very low-risk prostate cancer.","volume":"116","author":"Bratt","year":"2015","journal-title":"BJU Int"},{"issue":"5","key":"zoi240497r13","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1016\/j.juro.2013.05.054","article-title":"Population based study of use and determinants of active surveillance and watchful waiting for low and intermediate risk prostate cancer.","volume":"190","author":"Loeb","year":"2013","journal-title":"J Urol"},{"issue":"4","key":"zoi240497r14","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.eururo.2019.02.035","article-title":"The value of an extensive transrectal repeat biopsy with anterior sampling in men on active surveillance for low-risk prostate cancer: a comparison from the Randomised Study of Active Monitoring in Sweden (SAMS).","volume":"76","author":"Bratt","year":"2019","journal-title":"Eur Urol"},{"key":"zoi240497r15","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2147\/CLEP.S282475","article-title":"Adaptation of the Charlson Comorbidity Index for register-based research in Sweden.","volume":"13","author":"Ludvigsson","year":"2021","journal-title":"Clin Epidemiol"},{"issue":"2","key":"zoi240497r16","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/bco2.v3.2","article-title":"Mortality in men with castration-resistant prostate cancer\u2014a long-term follow-up of a population-based real-world cohort.","volume":"3","author":"Khoshkar","year":"2021","journal-title":"BJUI Compass"},{"key":"zoi240497r17","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.euros.2022.07.010","article-title":"Modeling disease trajectories for castration-resistant prostate cancer using nationwide population-based data.","volume":"44","author":"Ventimiglia","year":"2022","journal-title":"Eur Urol Open Sci"},{"issue":"9","key":"zoi240497r18","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.31015","article-title":"Long-term outcomes among men undergoing active surveillance for prostate cancer in Sweden.","volume":"5","author":"Ventimiglia","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"9","key":"zoi240497r19","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/S1470-2045(11)70162-0","article-title":"Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group-4 randomised trial.","volume":"12","author":"Johansson","year":"2011","journal-title":"Lancet Oncol"},{"issue":"8","key":"zoi240497r20","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.25600","article-title":"Association of gonadotropin-releasing hormone agonists for prostate cancer with cardiovascular disease risk and hypertension in men with diabetes.","volume":"5","author":"Lin","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"11","key":"zoi240497r22","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006590.pub2","article-title":"Radical prostatectomy versus watchful waiting for prostate cancer.","author":"Hegarty","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"issue":"17","key":"zoi240497r23","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1001\/jama.293.17.2095","article-title":"20-year outcomes following conservative management of clinically localized prostate cancer.","volume":"293","author":"Albertsen","year":"2005","journal-title":"JAMA"},{"issue":"6","key":"zoi240497r24","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.eururo.2020.02.009","article-title":"Radical prostatectomy or observation for clinically localized prostate cancer: extended follow-up of the Prostate Cancer Intervention Versus Observation Trial (PIVOT).","volume":"77","author":"Wilt","year":"2020","journal-title":"Eur Urol"},{"issue":"3","key":"zoi240497r25","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1111\/bju.2019.123.issue-3","article-title":"Mortality after radical prostatectomy in a matched contemporary cohort in Sweden compared to the Scandinavian Prostate Cancer Group 4 (SPCG-4) study.","volume":"123","author":"Cazzaniga","year":"2019","journal-title":"BJU Int"},{"issue":"4","key":"zoi240497r26","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1080\/21681805.2022.2107069","article-title":"How to survey adherence to guidelines by use of clinical cancer registers.","volume":"56","author":"Stattin","year":"2022","journal-title":"Scand J Urol"},{"issue":"4","key":"zoi240497r27","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1080\/21681805.2022.2094462","article-title":"The Swedish national guidelines on prostate cancer, part 1: early detection, diagnostics, staging, patient support and primary management of non-metastatic disease.","volume":"56","author":"Bratt","year":"2022","journal-title":"Scand J Urol"},{"issue":"10","key":"zoi240497r28","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1001\/jamaoncol.2016.3600","article-title":"Uptake of active surveillance for very-low-risk prostate cancer in Sweden.","volume":"3","author":"Loeb","year":"2017","journal-title":"JAMA Oncol"},{"issue":"7","key":"zoi240497r30","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1093\/jnci\/djk110","article-title":"Prostate-specific antigen levels as a predictor of lethal prostate cancer.","volume":"99","author":"Fall","year":"2007","journal-title":"J Natl Cancer Inst"},{"issue":"14","key":"zoi240497r31","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1111\/bju.v131.4","article-title":"Evidence of cancer progression as the cause of death in men with prostate cancer in Sweden.","volume":"131","author":"Orrason","year":"2023","journal-title":"BJU Int"},{"key":"zoi240497r2","unstructured":"EAU guidelines: prostate cancer. European Association of Urology. Accessed December 31, 2023. https:\/\/uroweb.org\/guidelines\/prostate-cancer"},{"key":"zoi240497r21","unstructured":"eurostat: databases. European Union. Accessed January 1, 2023. https:\/\/ec.europa.eu\/eurostat\/web\/main\/data\/database"},{"key":"zoi240497r29","unstructured":"RATTEN\u2014interactive on line report from NPCR of Sweden. National Prostate Cancer Register (NPCR) of Sweden. Accessed November 1, 2021. https:\/\/statistik.incanet.se\/npcr\/"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2819453\/ventimiglia_2024_oi_240497_1716576020.05476.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T17:30:44Z","timestamp":1717522244000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2819453"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,4]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.14599","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,4]]}}}